

42 - References

References

42 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. National Institute for Health and Care Excellence. Clinical Knowledge Summaries. Psychosis and schizophrenia: what monitoring is required? 2014 (last revised November 2021, checked January 2024); [https://cks.nice.org.uk/topics/psychosis--schizophrenia/prescribing-information/monitoring/#:~:text=References,What%20monitoring%20is%20required%3F, stabilized%20\(whichever%20is%20longer\).](https://cks.nice.org.uk/topics/psychosis--schizophrenia/prescribing-information/monitoring/#:~:text=References,What%20monitoring%20is%20required%3F, stabilized%20(whichever%20is%20longer).)
2. Bulteau S, et al. Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database. *Expert Opin Drug Saf* 2021; 20:225-233.
3. Lydon A, et al. Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study. *Ir J Psychol Med* 2021; 38:40-48.
4. Poojari PG, et al. Identification of risk factors and metabolic monitoring practices in patients on antipsychotic drugs in South India. *Asian J Psychiatr* 2020; 53:102186.
5. Perry BI, et al. Prolactin monitoring in the acute psychiatry setting. *Psychiatry Res* 2016; 235:104-109.
6. Burckart GJ, et al. Neutropenia following acute chlorpromazine ingestion. *Clin Toxicol* 1981; 18:797-801.
7. Montgomery J. Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia. *Gen Hosp Psychiatry* 2006; 28:83-85.
8. Cowan C, et al. Leukopenia and neutropenia induced by quetiapine. *Prog Neuropsychopharmacol Biol Psychiatry* 2007; 31:292-294.
9. Marder SR, et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 2004; 161:1334-1349.
10. Fenton WS, et al. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. *Am J Psychiatry* 2006; 163:1697-1704.
11. Taylor D, et al. Dopamine partial agonists: a discrete class of antipsychotics. *Int J Psychiatry Clin Pract* 2023; 27:272-284.
12. Weissman EM, et al. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. *J Clin Psychiatry* 2006; 67:1323-1326.
13. Cohn TA, et al. Metabolic monitoring for patients treated with antipsychotic medications. *Can J Psychiatry* 2006; 51:492-501.

14. Paton C, et al. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. *Acta Psychiatr Scand* 2004; 110:299–305.
15. Taylor D, et al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. *J Psychopharmacol* 2005; 19:182–186.
16. Citrome L, et al. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997–2004. *Psychiatr Serv* 2006; 57:1132–1139.
17. Barnes T, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. *J Psychopharm* 2020; 34:3–78.
18. Shah AA, et al. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? *J Psychiatr Pract* 2014; 20:196–206.
19. Novotny T, et al. Monitoring of QT interval in patients treated with psychotropic drugs. *Int J Cardiol* 2007; 117:329–332.
20. Ray WA, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med* 2009; 360:225–235.
21. Hummer M, et al. Hepatotoxicity of clozapine. *J Clin Psychopharmacol* 1997; 17:314–317.
22. Erdogan A, et al. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. *Int J Psychiatry Med* 2004; 34:83–89.
23. Regal RE, et al. Phenothiazine-induced cholestatic jaundice. *Clin Pharm* 1987; 6:787–794.
24. Centorrino F, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. *Am J Psychiatry* 2002; 159:109–115.
25. Gross A, et al. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. *Pharmacopsychiatry* 2004; 37:119–122.
26. Twaites BR, et al. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England. *J Psychopharmacol* 2007; 21:392–399.
27. Kelly DL, et al. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. *J Clin Psychiatry* 2005; 66:80–84.

Revision #1

Created 2026-01-04 20:13:44 UTC by Omar Ayman

Updated 2026-01-04 20:13:44 UTC by Omar Ayman